In this issue:
Inebilizumab for active IgG4-related disease
Depemokimab for CRSwNP
Long-term changes in the anti-SARS-CoV-2 antibody repertoire
Lunsekimig safety and tolerability
Characterising SARS-CoV-2-specific T cells in the lungs
Signalling pathways regulating IL-9 production
Efficacy of mepolizumab
The long-term effects of ruxolitinib
Elapegademase safety and tolerability
Oral mucosal immunotherapy INT301
Please login below to download this issue (PDF)